Infinity Pharmaceuticals (INFI) 10.15 $INFI
Infinity Pharmaceuticals Down 17.5% Since SmarTrend Downtrend Call (INFI)
Comtex SmarTrend(R) - Tue Apr 15, 9:17AM CDT
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on March 31st, 2014 at $12.03. In approximately 2 weeks, Infinity Pharmaceuticals has returned 17.54% as of today's recent price of $9.92.
Critical Alerts For LinkedIn, MGM Mirage, Coca Cola, SunEdison, and Infinity Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Apr 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LNKD, MGM, KO, SUNE, and INFI.
Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors
Business Wire - Tue Mar 11, 3:07PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has appointed Jose Baselga M.D., Ph.D. and Jeff Berkowitz as independent members of its board of directors. Dr. Baselga, physician-in-chief at Memorial Sloan Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. Mr. Berkowitz, as the President of Walgreens Boots Alliance Development, GmbH (WAG) in Europe, has a wealth of experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement.
Infinity to Present at the Upcoming Bernstein Emerging Biotech Conference
Business Wire - Mon Mar 03, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Bernstein Emerging Biotech Conference 2014 on Monday, March 10th at 4:00 p.m. MT in Snowbird, Utah.
Infinity Pharma Rises on Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 10:20AM CST
Infinity Pharma reported a loss of 68 cents per share in the fourth quarter narrower than the Zacks Consensus Estimate of a loss of 83 cents.
Critical Alerts For InterMune, Infinity Pharmaceuticals, Zulily, Intrexon, and Polypore International Released By InvestorsObserver
PR Newswire - Wed Feb 26, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ITMN, INFI, ZU, XON, and PPO.
Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:51AM CST
Infinity Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 16% on the day.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why InterMune, Zulily, and Infinity Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Even when the economic data isn't ugly, as it had been during...
Why Infinity Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 12:19PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Infinity Pharmaceuticals , a...
Infinity Provides Company Update and Reports Full-Year 2013 Financial Results
Business Wire - Tue Feb 25, 7:03AM CST
--- Phase 3 Study, DUO(TM), in Patients with Relapsed/Refractory CLL Under Way -
Direct Energy Revenue Up 28% in 2013
PR Newswire - Thu Feb 20, 1:15AM CST
Direct Energy, North America's largest competitive energy and energy-related services company, today announced gross revenue for the full year 2013 of US $11.4 billion (£7.3 billion), an increase of 28 percent, and an operating profit of US$436 million (£276 million). Direct Energy is the North American subsidiary of Centrica plc (LSE: CNA). Centrica reported full year 2013 revenues of US$41.6 billion (£26.6 billion) with an operating profit of US$4.2 billion (£2.7 billion).
Infinity to Participate in 3 Upcoming Conferences
Business Wire - Wed Feb 19, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following 3 upcoming conferences:
The Hidden Gems in Gilead Sciences' Pipeline
Leo Sun, The Motley Fool - Motley Fool - Thu Feb 13, 1:30PM CST
When most biotech investors think about Gilead Sciences , they usually think of the company's portfolio of antiviral drugs and its newly approved potential blockbuster hepatitis C treatment, Sovaldi. Gilead's antiviral portfolio,...
Infinity Announces the Date of Its Full-Year 2013 Financial Results Conference Call and Webcast
Business Wire - Tue Feb 11, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, February 25, 2014, at 8:30 a.m. ET. During the call, management will review the company's full-year 2013 financial results and provide an update on Infinity's business.
Infinity Announces Promotion of David A. Roth to Chief Medical Officer
Business Wire - Tue Feb 04, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the promotion of David A. Roth, M.D., to chief medical officer. In this role, Dr. Roth will provide strategic leadership for Infinity's clinical development activities, including responsibility for the company's medical affairs and clinical operations functions to support successful product approvals and launches. Dr. Roth, who joined Infinity in 2013 as senior vice president, clinical development and medical affairs, will continue to serve as a member of Infinity's executive leadership team and will report to Julian Adams, Ph.D., Infinity's president of research and development. In accordance with the company's management succession plan, Dr. Roth succeeds Pedro Santabarbara, M.D., Ph.D., who previously served as Infinity's chief medical officer.
Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum
Business Wire - Thu Jan 23, 3:00PM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported encouraging data from its ongoing Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed/refractory T-cell lymphoma, a difficult-to-treat hematologic malignancy (blood cancer) with few available treatment options. Preliminary data showed that IPI-145 is clinically active in patients with T-cell lymphoma, with an overall response rate of 38 percent, including one complete response and nine partial responses among 26 patients evaluable for response. These findings were reported during the 6th Annual T-Cell Lymphoma Forum being held from January 23 - 25, 2014, in San Francisco, CA.
Infinity Provides Key 2014 Goals and Financial Guidance
Business Wire - Mon Jan 13, 7:00AM CST
--- Topline Data from Phase 2 Study of IPI-145 in Rheumatoid Arthritis Expected In 2014 -
Infinity Pharmaceuticals Down 17.5% Since SmarTrend Downtrend Call (INFI)
Comtex SmarTrend(R) - Tue Apr 15, 9:17AM CDT
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on March 31st, 2014 at $12.03. In approximately 2 weeks, Infinity Pharmaceuticals has returned 17.54% as of today's recent price of $9.92.
Critical Alerts For LinkedIn, MGM Mirage, Coca Cola, SunEdison, and Infinity Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Apr 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LNKD, MGM, KO, SUNE, and INFI.
Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors
Business Wire - Tue Mar 11, 3:07PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has appointed Jose Baselga M.D., Ph.D. and Jeff Berkowitz as independent members of its board of directors. Dr. Baselga, physician-in-chief at Memorial Sloan Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. Mr. Berkowitz, as the President of Walgreens Boots Alliance Development, GmbH (WAG) in Europe, has a wealth of experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement.
Infinity to Present at the Upcoming Bernstein Emerging Biotech Conference
Business Wire - Mon Mar 03, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Bernstein Emerging Biotech Conference 2014 on Monday, March 10th at 4:00 p.m. MT in Snowbird, Utah.
Infinity Pharma Rises on Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 10:20AM CST
Infinity Pharma reported a loss of 68 cents per share in the fourth quarter narrower than the Zacks Consensus Estimate of a loss of 83 cents.
Critical Alerts For InterMune, Infinity Pharmaceuticals, Zulily, Intrexon, and Polypore International Released By InvestorsObserver
PR Newswire - Wed Feb 26, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ITMN, INFI, ZU, XON, and PPO.
Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:51AM CST
Infinity Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 16% on the day.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why InterMune, Zulily, and Infinity Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Even when the economic data isn't ugly, as it had been during...
Why Infinity Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 12:19PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Infinity Pharmaceuticals , a...
Infinity Provides Company Update and Reports Full-Year 2013 Financial Results
Business Wire - Tue Feb 25, 7:03AM CST
--- Phase 3 Study, DUO(TM), in Patients with Relapsed/Refractory CLL Under Way -
Direct Energy Revenue Up 28% in 2013
PR Newswire - Thu Feb 20, 1:15AM CST
Direct Energy, North America's largest competitive energy and energy-related services company, today announced gross revenue for the full year 2013 of US $11.4 billion (£7.3 billion), an increase of 28 percent, and an operating profit of US$436 million (£276 million). Direct Energy is the North American subsidiary of Centrica plc (LSE: CNA). Centrica reported full year 2013 revenues of US$41.6 billion (£26.6 billion) with an operating profit of US$4.2 billion (£2.7 billion).
Infinity to Participate in 3 Upcoming Conferences
Business Wire - Wed Feb 19, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following 3 upcoming conferences:
The Hidden Gems in Gilead Sciences' Pipeline
Leo Sun, The Motley Fool - Motley Fool - Thu Feb 13, 1:30PM CST
When most biotech investors think about Gilead Sciences , they usually think of the company's portfolio of antiviral drugs and its newly approved potential blockbuster hepatitis C treatment, Sovaldi. Gilead's antiviral portfolio,...
Infinity Announces the Date of Its Full-Year 2013 Financial Results Conference Call and Webcast
Business Wire - Tue Feb 11, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, February 25, 2014, at 8:30 a.m. ET. During the call, management will review the company's full-year 2013 financial results and provide an update on Infinity's business.
Infinity Announces Promotion of David A. Roth to Chief Medical Officer
Business Wire - Tue Feb 04, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the promotion of David A. Roth, M.D., to chief medical officer. In this role, Dr. Roth will provide strategic leadership for Infinity's clinical development activities, including responsibility for the company's medical affairs and clinical operations functions to support successful product approvals and launches. Dr. Roth, who joined Infinity in 2013 as senior vice president, clinical development and medical affairs, will continue to serve as a member of Infinity's executive leadership team and will report to Julian Adams, Ph.D., Infinity's president of research and development. In accordance with the company's management succession plan, Dr. Roth succeeds Pedro Santabarbara, M.D., Ph.D., who previously served as Infinity's chief medical officer.
Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum
Business Wire - Thu Jan 23, 3:00PM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported encouraging data from its ongoing Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed/refractory T-cell lymphoma, a difficult-to-treat hematologic malignancy (blood cancer) with few available treatment options. Preliminary data showed that IPI-145 is clinically active in patients with T-cell lymphoma, with an overall response rate of 38 percent, including one complete response and nine partial responses among 26 patients evaluable for response. These findings were reported during the 6th Annual T-Cell Lymphoma Forum being held from January 23 - 25, 2014, in San Francisco, CA.
Infinity Provides Key 2014 Goals and Financial Guidance
Business Wire - Mon Jan 13, 7:00AM CST
--- Topline Data from Phase 2 Study of IPI-145 in Rheumatoid Arthritis Expected In 2014 -
